Cellectis S.A.(CLLS)Earnings, Financials & Key RatiosCellectis S.A. (CLLS) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's reliance on non-recurring milestones and the rapid depletion of its cash buffer to $35.0 million in 2026Q1 present significant insolvency risks for long-term investors.
Cellectis S.A. (CLLS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Cellectis S.A. (CLLS) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 11, 2026 | $0.18vs $0.26+30.3% | $8Mvs $11M-31.6% |
| Q2 2026 | Mar 19, 2026 | $0.26vs $0.20-27.9% | $12Mvs $13M-8.9% |
| Q4 2025 | Nov 7, 2025 | $0.01vs $0.10+110.0% | $35Mvs $10M+242.4% |
| Q3 2025 | Aug 4, 2025 | $0.24vs $0.10-140.0% | $17Mvs $8M+106.0% |
Recent stock market news and headlines for Cellectis S.A. (CLLS)
NEW YORK, June 25, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, held today its shareholders general meeting at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France.
Key metrics vs top competitors for Cellectis S.A. (CLLS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $3.22 | $323.31M | -4.74 | 75.76% | -92.66% | -65.33% | — | |
| $60.77 | $5.86B | -9.39 | -89.97% | -13856.54% | -30.88% | — | |
| $37.92 | $3.9B | -46.81 | 120.01% | -49.17% | -5.89% | — | |
| $3.75 | $367.15M | -2.08 | 25.39% | -281.59% | -677.39% | — | |
| $17.43 | $1.96B | -4.57 | 16.92% | -597.04% | -57.27% | — | |
| $3.02 | $352.01M | -2.63 | -51.24% | -2056.79% | -58.89% | — |
Cellectis S.A. (CLLS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when CLLS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Cellectis S.A. (CLLS) stock FAQ — growth, dividends, profitability & financials explained
Cellectis S.A. (CLLS) reported $68.1M in revenue for fiscal year 2025. This represents a 1560% increase from $4.1M in 2007.
Cellectis S.A. (CLLS) grew revenue by 75.8% over the past year. This is strong growth.
Cellectis S.A. (CLLS) reported a net loss of $67.3M for fiscal year 2025.
Cellectis S.A. (CLLS) has a return on equity (ROE) of -65.3%. Negative ROE indicates the company is unprofitable.
Cellectis S.A. (CLLS) had negative free cash flow of $40.1M in fiscal year 2025, likely due to heavy capital investments.
